Pricing
  1. US-listed companies
  2. CymaBay Therapeutics, Inc.
  3. Financials
  4. Free cash flow

CymaBay Therapeutics, Inc. (CBAY)

Market cap
$3.7B
P/E ratio
SummaryFinancials
Period EndFree cash flow (Million USD)YoY (%)
Dec 31, 2023-73-13.42%
Dec 31, 2022-84+21.24%
Dec 31, 2021-69+55.38%
Dec 31, 2020-45-54.47%
Dec 31, 2019-98+77.08%
Dec 31, 2018-55+182.14%
Dec 31, 2017-20-15.97%
Dec 31, 2016-23+10.27%
Dec 31, 2014-21

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat